PET/MR and PET/CT Imaging for Parathyroid Cancer

This trial aims to improve the detection of parathyroid tumors before surgery using advanced imaging scans. It will compare PET/MRI and NeuroEXPLORER PET-CT scans with a special tracer (18F-FCH, a radioactive compound used in imaging) against current imaging methods. The trial targets individuals scheduled for parathyroid gland removal, particularly those with primary hyperparathyroidism or suspected parathyroid cancer. Participants will undergo several imaging sessions and a follow-up after surgery to evaluate the new scans' effectiveness. As a Phase 2, Phase 3 trial, this research assesses the performance of the new imaging methods in preparation for potential FDA approval, allowing participants to contribute to advancements in medical imaging.

The trial information does not specify if you need to stop taking your current medications. However, if you are using any investigational products or devices, you must stop them at least 30 days before the 18F-FCH scan.

Research has shown that 18F-fluorocholine (18F-FCH) is generally safe and well-tolerated. Studies have found it to be a safe substance for use in imaging scans. One study demonstrated that 18F-FCH PET scans successfully identified parathyroid tumors in 93% of patients, proving especially helpful when other methods failed.

Importantly, these studies reported no major side effects in participants. Although the tracer collects in some other tissues, this has not led to any significant safety issues.

Researchers are excited about the use of 18F-FCH in imaging for parathyroid cancer because it provides a more precise way to locate cancerous tissues compared to traditional imaging techniques like ultrasound or standard CT scans. 18F-FCH is a radioactive tracer that highlights parathyroid cancer cells during PET/CT and PET/MRI scans, offering high-resolution images that can lead to better diagnosis and treatment planning. This method could enhance the accuracy of tumor detection, potentially improving outcomes for patients with parathyroid cancer.

Studies have shown that the 18F-FCH tracer used in PET scans effectively detects parathyroid tumors. Research indicates that this tracer surpasses older imaging methods like ultrasound or SPECT in accuracy. Specifically, one study found that 18F-FCH PET/CT correctly identified tumors in up to 91.7% of cases. Other studies have confirmed its effectiveness for both new and recurrent cases of parathyroid disease. Overall, 18F-FCH PET scans are considered reliable for locating these elusive glands before surgery. Participants in this trial will receive an 18F-FCH injection for use in PET/CT and PET/MRI imaging.⁵⁶⁷⁸⁹